Finally, there are many risks associated with longer stays: infections; blood clots; muscle weakening and pressure sores, to ...
The Briefing Room – what next for healthcare communications?
The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...
Too often, people suffer in silence because of deeply rooted taboos around certain health conditions. While these stigmas are ...
The fear that machines would replace humans within months was quickly replaced with a new narrative that, far from making ...
The NHS in 2026 is facing a familiar but intensifying oncology challenge. Our data at HSJ Information shows rising incidence, ...
For decades, the UK’s pharmaceutical and biotech sectors have been leaders in discovery and innovation. Yet as the cost of ...
Ten exciting new pharmaceutical drugs emerging in 2026 ...
HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in patients with unresectable, advanced or metastatic solid tumours in China and ...
Bioxytran has announced encouraging results from a randomized, double‑blind, placebo‑controlled phase 1b/2a study of its oral ...
The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...
AlzeCure Pharma has announced that the European Medicines Agency has granted orphan drug status to ACD440, its clinical‑stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results